8-K: Envoy Medical Enters $15 Million At-The-Market Offering Agreement with Roth Capital Partners

Envoy Medical, Inc. has entered into an agreement with Roth Capital Partners to sell up to $15 million of its Class A common stock through an at-the-market offering.

Summary

• Envoy Medical, Inc. has entered into an At The Market Offering Agreement with Roth Capital Partners, LLC, effective January 17, 2025.
• Under the agreement, Roth Capital Partners will act as Envoy Medical's agent for the sale of Class A common stock.
• Envoy Medical may sell shares up to an aggregate offering amount of $15 million.
• Sales will be made through 'at the market' offerings as defined in Rule 415 under the Securities Act of 1933.
• The shares will be sold under Envoy Medical's existing Registration Statement on Form S-3.
• Envoy Medical is not obligated to sell any shares and there is no guarantee that any shares will be sold.
• The offering can be suspended or terminated by either Envoy Medical or Roth Capital Partners.
• Roth Capital Partners will receive a cash commission of up to 3.0% of the gross proceeds from each sale of shares.
• Envoy Medical will reimburse Roth Capital Partners for legal counsel fees up to $50,000.
• The Sales Agreement contains customary representations, warranties, and covenants from Envoy Medical, including indemnification of the Sales Agent.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The announcement is a standard financial transaction (ATM offering). While it provides the company with potential capital, it also introduces potential dilution for existing shareholders.

Positives

• Envoy Medical gains access to capital through an at-the-market offering, providing flexibility in raising funds.
• The company has the discretion to control the timing and amount of shares sold.
• The offering is made under an existing registration statement, streamlining the process.
• The agreement includes standard indemnification provisions, protecting both parties.

Negatives

• There is no guarantee that Envoy Medical will sell any shares or raise the full $15 million.
• The company will incur commission expenses of up to 3.0% on any shares sold.
• The offering could potentially dilute existing shareholders' equity.
• The company is subject to customary representations, warranties, and covenants, increasing potential liability.

Risks

• Market conditions could impact the price and volume of shares sold.
• The company's stock price could be negatively affected by the offering.
• Failure to comply with the terms of the Sales Agreement could result in penalties or termination.
• The company's reliance on Roth Capital Partners for sales could limit its access to other potential investors.

Future Outlook

The company may offer and sell shares of its Class A common stock from time to time, at its discretion, through Roth Capital Partners. The actual amount and timing of any sales are uncertain.

Industry Context

At-the-market offerings are a common method for companies to raise capital, providing flexibility and control over the sales process. This type of offering allows companies to take advantage of favorable market conditions and raise funds as needed.

Comparison to Industry Standards

• At-the-market offerings are frequently used by small to mid-cap companies in the biotech and medical device sectors.
• Comparable companies like Second Sight Medical Products and Nano-X Imaging have utilized similar ATM offerings to fund operations and research.
• The commission rate of 3.0% is within the typical range for ATM offerings, which generally vary between 1% and 5% depending on the size and complexity of the offering.
• The legal fee reimbursement cap of $50,000 is also standard for these types of agreements.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company's financial position could be strengthened by the additional capital raised.
• Employees may benefit from the company's increased financial stability.
• Customers and suppliers may see continued operations and investment in the company's products and services.

Next Steps

• Envoy Medical may begin selling shares of its Class A common stock through Roth Capital Partners.
• The company will file a prospectus supplement with the SEC in connection with the offering.
• Roth Capital Partners will work to sell the shares at the market price, subject to the company's instructions.
• The company will monitor market conditions and adjust its sales strategy as needed.

Key Dates